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Abstract

miR-216a/217 expression KC progression mouse model
and human PC tissue

Expression of miR-216a/217 in PC (GSE41369 data set )
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Overexpression of miR-216a/217 reduced cell proliferation and
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Fig 1. A&B. Expression of miR-216a/217 cluster during pancreatic cancer
progression. C&D. miR-216a/217 expression in normal vs PC tissue.

Mean +/− SEM (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.001 n ≥ 3)

In-silico analysis for shortlisting the direct binding of gene involved in EMT
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Fig 2. A. miR-216a/217 expression in human PC tissues samples B. miR-216a/217
expression pattern in KC progression mouse model. C. miR-216a/217 expression
(In-situ hybridization) in tumor adjacent normal and PC tissues (TMA- 196 core).
Mean +/− SEM (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.001 n ≥ 3)
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Pancreatic cancer (PC) is a lethal malignancy with a 5-year
survival rate of 10.8%. Gemcitabine, in combination with
Abraxane and Folfirinox, are current treatments available for
metastatic PC, however, all these therapies provided limited
patient survival benefit, often resulting in high toxicity.
Therefore, there is a need to identify novel therapeutic targets
and combination therapies to combat this lethal cancer.
MicroRNAs (miRNAs or miRs) have been shown to regulate PC
proliferation and metastasis. Recently, miRNA therapies have
shown promising results as a single miRNA is predicted to
target more than 200 genes, involved in multiple pathways. The
objective of this study is to understand the role of miR-216a/217
in PC growth and its progression. We and others have shown
that miR-216a/217 was progressively downregulated during PC
progression. PC patients with higher miR-216a/217 had better
survival. Our In-situ hybridization data showed reduced
expression of miR-216a/217 in PC patient samples (TMA - 196
core). Further, over-expression of miR-216a/217 in Capan-1 PC
cells in vitro resulted in inhibition of cell proliferation and the
epithelial-mesenchymal transition (EMT). In silico analysis have
identified protein tyrosine phosphatase type IVA member 1
(PTP4A1) as a direct downstream target of miR-216a/217 in
PC. Furthermore, our data indicates that miR-216a/217 inhibits
PC metastasis by targeting PTP4A1 and may serve as a
prospective therapeutic target in PC.

Results
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Fig 3. A. Expression of miR-216a/217 in parental and overexpressed Capan-1 cells. B.
Graph represents the expression of miR-216a and miR-217 expression in Capan-1 cells by
TaqMan assay. C. Western Blots of proliferation markers. D. Western Blots of EMT markers.
Mean +/− SEM (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.001 n ≥ 3)

PTP4A1 could be a promising target for miR-216a/217
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Aim
The aim of the current study is to understand the role of miR216a/217 in pancreatic cancer growth and its progression.

Fig 4. A. Venn diagram intersection shows list of genes that could be a direct target for miR-216a/217 B. Top 10 genes that could be direct target
for miR-216a/217 C. List of pathways for top 10 genes involved. D. Expression levels of the top 10 genes in normal vs PC vs metastasis E. String
analysis for PTP4A1

Fig 5. A. PTP4A1 expression in normal and tumorous tissue. B. PTP4A1 survival curve. C. target scan
shows direct complementarity of miR-216a/217 and 3’UTR of PTP4A1.

Future Directions
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• We will perform various in vitro and in vivo functional assays to
assess miR-216a/217 role in proliferation, migration, invasion
tumorigenicity and metastasis.
• RNA sequencing of PC cells overexpressing miR-216a/217
cluster to delineate the molecular mechanism(s).
• We will validate the direct binding of miR-216a/217 to the
3’UTR region of PTP4A1 gene by dual luciferase assay.
• siRNA of PTP4A1 in PC cell line and OE PTP4A1 w/o 3’UTR
region of PTP4A1 in miR-216a/217 OE PC cells.

• miR-216a/217 are down regulated in PC.
• Restoration of miR-216a/217 showed reduced cell proliferation and EMT
markers in pancreatic cancer.
• In silico analysis revealed that PTP4A1 could be a promising target gene via
target-scan analysis.
• PTP4A1 showed increased expression in metastatic tumors suggesting that
it could be an important target gene involved in EMT.
• Thus, restoring miR-216a/217 could be one of the potential therapies in PC.
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